The Role of TROP2 in Non-Small Cell Lung Cancer

Drs. Benjamin Levy and David Rimm introduce the evolving role of TROP2 as a therapeutic target in non–small cell lung cancer and frame the key questions driving current research. They outline why TROP2 has gained attention across both squamous and non-squamous histologies and review data suggesting that high expression may be associated with worse outcomes. The discussion establishes the clinical relevance of antibody drug conjugates directed against TROP2 and explores whether these agents should be viewed as targeted therapies or as cytotoxic drugs with targeted delivery. By setting the biological and clinical context, Drs. Levy and Rimm prepare viewers to understand why accurate biomarker assessment is critical and why conventional approaches may be insufficient. The conversation emphasizes the need to better define how TROP2 should be measured and interpreted as new therapies continue to enter the lung cancer treatment landscape.